Insomnia Treatment in Older Adults
Cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment for chronic insomnia in older adults [1], VA/DoD 2025 insomnia guideline.
When medication is necessary, benzodiazepines and Z-drugs should generally be avoided because of adverse event risk in older adults [2].
Initial Evaluation and Reversible Contributors
Insomnia should be evaluated for contributing comorbidities and medications before insomnia-specific treatment VA/DoD 2025 insomnia guideline.
Basic assessment should include:
- Sleep timing, sleep–wake schedule, and insomnia pattern (sleep-onset vs maintenance vs both) VA/DoD 2025 insomnia guideline.
- Substance and medication review for agents that worsen sleep (example categories: sedatives, stimulants, some antidepressants, corticosteroids) VA/DoD 2025 insomnia guideline.
- Screening for obstructive sleep apnea when clinically suggested, because untreated sleep-disordered breathing can maintain insomnia symptoms VA/DoD 2025 insomnia guideline.
CBT-I Components and Delivery Options
Multicomponent CBT-I is recommended for chronic insomnia in adults [1].
CBT-I typically includes:
- Stimulus control therapy [1].
- Sleep restriction therapy [1].
- Cognitive therapy strategies targeting maladaptive sleep beliefs [1].
Digital CBT-I is supported as an evidence-based delivery format in older adults [3].
Medication Selection Algorithm (When Pharmacotherapy Is Required)
Medication use should be reserved for cases where symptoms persist despite CBT-I access or where CBT-I cannot be implemented initially VA/DoD 2025 insomnia guideline.
Medication selection should prioritize agents with a safer geriatric adverse-effect profile:
- Dual orexin receptor antagonists (DORAs) (examples: suvorexant, lemborexant, daridorexant) are associated with a favorable efficacy–safety balance in older adults in contemporary evidence synthesis [3].
-
Melatonin (extended-release melatonin in ≥55 years populations in one expert consensus) is proposed as a preferred option for older adults in that consensus document [4].
Agents generally avoided because of harm risk in older adults: -
Benzodiazepines [2].
- Z-drugs (zolpidem, eszopiclone, zaleplon) [2].
Monotherapy Versus Combination Therapy
CBT-I should remain the core treatment.
Medication use should generally be time-limited and paired with CBT-I to reduce ongoing hypnotic exposure VA/DoD 2025 insomnia guideline.
Initiation Thresholds and Practical Start Points
Chronic insomnia treatment should begin with CBT-I as first-line therapy [1], VA/DoD 2025 insomnia guideline.
Pharmacotherapy should be considered when:
- CBT-I access is not feasible or symptoms require short-term pharmacologic bridging VA/DoD 2025 insomnia guideline.
- Ongoing insomnia persists and functional impairment continues despite behavioral treatment attempts VA/DoD 2025 insomnia guideline.
Key Evidence in Older Adults
CBT-I produced clinically meaningful sleep improvements in geriatric trials summarized in a 2026 systematic review, including:
- Sleep efficiency improvement (mean difference +8.36%) [3].
-
Wake after sleep onset reduction (mean difference −23.44 minutes) [3].
DORAs showed consistent benefit for sleep initiation in older adults in the same systematic review: -
Subjective time to sleep onset standardized mean difference −0.28 (95% CI −0.41 to −0.15) [3].
Older hypnotics increase safety risks: -
Benzodiazepines and Z-drugs were associated with increased fall risk in the 2026 systematic review (risk ratio approximately 1.47) [3].
Common Pitfalls to Avoid
Sedative-hypnotic exposure is a key risk driver in older adults.
Benzodiazepines and Z-drugs are potentially inappropriate medications in older adults because of increased risk of falls, cognitive impairment, and delirium [2].
Sleep hygiene advice alone is insufficient when chronic insomnia persists.
CBT-I should not be replaced by sleep hygiene education alone when insomnia is chronic VA/DoD 2025 insomnia guideline.
Treatment Goals and Follow-Up Targets
The treatment goal is improvement in insomnia severity and sleep continuity with reduction in daytime impairment.
CBT-I is expected to improve insomnia severity and sleep quality outcomes in older adults [1], [3].
Follow-up should track response and adverse effects and should support deprescribing when medication is used short term VA/DoD 2025 insomnia guideline.